Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial.
Barlow-Mosha LN, Ahimbisibwe GM, Chappell E, Amuge PM, Nanduudu A, Kaudha E, Amukele T, Balamusani D, Kafufu B, Nimwesiga A, Kataike H, Namwanje R, Kasangaki G, Mulindwa A, Muzorah GA, Bbuye D, Musiime V, Mujyambere E, Ssenyonga M, Mulima D, Kyambadde RC, Namusanje J, Isabirye R, Nabalamba M, Nakirya BM, Kityo C, Kekitiinwa AR, Giaquinto C, Copp A, Gibb DM, Ford D, Musoke P, Turkova A; ODYSSEY trial team. Barlow-Mosha LN, et al. Among authors: gibb dm. J Int AIDS Soc. 2023 Sep;26(9):e26174. doi: 10.1002/jia2.26174. J Int AIDS Soc. 2023. PMID: 37766505 Free PMC article. Clinical Trial.
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team. Kasirye P, et al. Among authors: gibb dm. Clin Pharmacol Ther. 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21. Clin Pharmacol Ther. 2012. PMID: 22190066
Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe.
Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, Musoke P, Gibb DM; ARROW Trial Team. Musiime V, et al. Among authors: gibb dm. Pediatr Infect Dis J. 2013 Aug;32(8):856-62. doi: 10.1097/INF.0b013e31828c3991. Pediatr Infect Dis J. 2013. PMID: 23407100 Clinical Trial.
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Komunyena J, Kabamba D, Asiimwe AR, Mirembe G, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Walker SA, Klein N, Gibb DM; CHAPAS-3 trial team. Musiime V, et al. Among authors: gibb dm. Antivir Ther. 2014;19(3):269-76. doi: 10.3851/IMP2695. Epub 2013 Oct 25. Antivir Ther. 2014. PMID: 24717427 Clinical Trial.
Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
Fillekes Q, Kendall L, Kitaka S, Mugyenyi P, Musoke P, Ndigendawani M, Bwakura-Dangarembizi M, Gibb DM, Burger D, Walker AS; ARROW Trial Team. Fillekes Q, et al. Among authors: gibb dm. Pediatr Infect Dis J. 2014 May;33(5):495-8. doi: 10.1097/INF.0000000000000143. Pediatr Infect Dis J. 2014. PMID: 24736440 Free PMC article. Clinical Trial.
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team. Bwakura-Dangarembizi M, et al. Among authors: gibb dm. Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491. Pediatr Infect Dis J. 2015. PMID: 25068287 Free PMC article.
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.
Compagnucci A, Chan MK, Saïdi Y, Cressey TR, Bamford A, Riault Y, Coelho A, Nolan A, Chalermpantmetagul S, Morkunaite G, Amuge P, Musiime V, Violari A, Cotton M, Kekitiinwa AR, Kaudha E, Groenewald M, Liberty AA, Kanjanavanit S, Volokha A, Bologna R, Pavia Ruz N, Prieto Tato L, Paioni P, Marques L, Reliquet V, Niehues T, Welch SB, Ford D, Giaquinto C, Gibb DM, Babiker A, Ramos Amador JT; SMILE-PENTA17-ANRS 152 Trial Group. Compagnucci A, et al. Among authors: gibb dm. EClinicalMedicine. 2023 Jun 2;60:102025. doi: 10.1016/j.eclinm.2023.102025. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37304494 Free PMC article.
364 results